News about general reimbursement of medicines
-
Three new reimbursement guidelines
| 03 April 2018 |
The Danish Medicines Agency has issued three new guidelines on reimbursement (in Danish only). This regards Guideline on application for general reimbursement and general conditional reimbursement, Guideline on periodic reassessment of the reimbursement status of medicines and Guideline on the making of health economic analyses of medicines.
-
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
| 08 March 2012 |
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 06 March 2012 |
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
-
Decision on general conditional reimbursement for alendronate-containing medicines
| 22 February 2012 |
In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bones).
-
Applications for general reimbursement in 2011
| 02 February 2012 |
In 2011, we reviewed 21 applications for general reimbursement for 20 different medicinal products. 15 of the applications ended with the granting of general reimbursement or general conditional reimbursement, and the remaining six applications were refused.
-
Review concluded regarding general reimbursement for Xarelto®
| 25 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for two new strengths of Xarelto®. The product maintains general reimbursement.
-
Review concluded regarding general reimbursement for Zomig Nasal®
| 20 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Zomig Nasal®. The product has been granted general reimbursement.
-
Decision on general reimbursement for Yellox®
| 17 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Yellox®. The product has been granted general reimbursement.
-
Review concluded regarding general reimbursement for Multaq®
| 16 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Multaq®. The product is neither eligible for general nor general conditional reimbursement.
-
Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 13 January 2012 |
On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetics.
-
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)
| 05 January 2012 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.
-
Comments received on the reassessment of reimbursement status of strong analgesics (opioids)
| 04 November 2011 |
The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.
-
Changed reimbursement for medicines for depression and anxiety as of 5 March 2012
| 07 October 2011 |
With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelatine).
-
The reimbursement for glucosamine is removed on 28 November 2011
| 04 October 2011 |
The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.
-
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines
| 20 September 2011 |
The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.
-
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)
| 20 September 2011 |
The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.
-
Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine
| 26 August 2011 |
On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.
-
Reassessment of reimbursement status of strong analgesics (opioids)
| 15 August 2011 |
On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N (nervous system) starting with the ATC subgroup N06A (antidepressants) and then N02A (opioids). The Reimbursement Committee is having the initial discussions of the opioids at its meeting on 23 August 2011.
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)
| 05 July 2011 |
At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).
-
Decision on future reimbursement status of medicines in ATC group C05 (vasoprotectives)
| 28 June 2011 |
On 27 June 2011, the Danish Medicines Agency decided on the future reimbursement status of medicines in ATC group C05 (vasoprotectives). These medicines will still not be eligible for general reimbursement.